Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innovent Biologics ( (HK:1801) ) has shared an announcement.
Innovent Biologics has granted 1,935,642 share options to 66 grantees, including directors and senior management, and 10,241,272 restricted shares to 1,308 grantees under its 2024 Share Scheme, with options exercisable at HK$86.10 per share over a 10-year period. The awards, which feature staggered vesting schedules and performance-linked conditions for most employees but not for independent non-executive directors, are designed to incentivize key personnel, align their interests with shareholders and support the company’s long-term growth and governance framework.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$113.86 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a Cayman Islands–incorporated biopharmaceutical company listed in Hong Kong, focused on developing and commercializing innovative biologic therapies. The group’s operations span research and development, chemistry manufacturing and controls, commercialization and related supporting functions aimed at advancing its drug pipeline and market presence.
Average Trading Volume: 11,247,086
Technical Sentiment Signal: Buy
Current Market Cap: HK$148.4B
For an in-depth examination of 1801 stock, go to TipRanks’ Overview page.